202 related articles for article (PubMed ID: 24802970)
1. High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures.
Penfornis P; Cai DZ; Harris MR; Walker R; Licini D; Fernandes JD; Orr G; Koganti T; Hicks C; Induru S; Meyer MS; Khokha R; Barr J; Pochampally RR
Cancer Med; 2014 Aug; 3(4):796-811. PubMed ID: 24802970
[TBL] [Abstract][Full Text] [Related]
2. Human osteosarcoma CD49f(-)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity.
Ying M; Liu G; Shimada H; Ding W; May WA; He Q; Adams GB; Wu L
Oncogene; 2013 Sep; 32(36):4252-63. PubMed ID: 23045288
[TBL] [Abstract][Full Text] [Related]
3. CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors.
Fukamachi H; Seol HS; Shimada S; Funasaka C; Baba K; Kim JH; Park YS; Kim MJ; Kato K; Inokuchi M; Kawachi H; Yook JH; Eishi Y; Kojima K; Kim WH; Jang SJ; Yuasa Y
PLoS One; 2013; 8(8):e72438. PubMed ID: 24015244
[TBL] [Abstract][Full Text] [Related]
4. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma.
Le Nail LR; Brennan M; Rosset P; Deschaseaux F; Piloquet P; Pichon O; Le Caignec C; Crenn V; Layrolle P; Hérault O; De Pinieux G; Trichet V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29494553
[TBL] [Abstract][Full Text] [Related]
6. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
7. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
[TBL] [Abstract][Full Text] [Related]
8. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
10. lncRNA nuclear-enriched abundant transcript 1 promotes cell proliferation and invasion by targeting miR-186-5p/HIF-1α in osteosarcoma.
Tan H; Zhao L
J Cell Biochem; 2019 Apr; 120(4):6502-6514. PubMed ID: 30485482
[TBL] [Abstract][Full Text] [Related]
11. KIAA1429 promotes osteosarcoma progression by promoting stem cell properties and is regulated by miR-143-3p.
Han Q; Yang J; Yang H; Li C; Li J; Cao Y
Cell Cycle; 2020 May; 19(10):1172-1185. PubMed ID: 32286148
[No Abstract] [Full Text] [Related]
12. CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.
Li X; Xu R; Liu H; Fang K
Tumour Biol; 2016 Jun; 37(6):8139-44. PubMed ID: 26715273
[TBL] [Abstract][Full Text] [Related]
13. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
14. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition.
Wang W; Chen D; Zhu K
J Exp Clin Cancer Res; 2018 Feb; 37(1):37. PubMed ID: 29475441
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
Yang C; Wu K; Wang S; Wei G
J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
[TBL] [Abstract][Full Text] [Related]
16. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
17. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma.
Kubota D; Mukaihara K; Yoshida A; Tsuda H; Kawai A; Kondo T
J Proteomics; 2013 Oct; 91():393-404. PubMed ID: 23911960
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line.
Martins-Neves SR; Lopes ÁO; do Carmo A; Paiva AA; Simões PC; Abrunhosa AJ; Gomes CM
BMC Cancer; 2012 Apr; 12():139. PubMed ID: 22475227
[TBL] [Abstract][Full Text] [Related]
19. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
20. TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells.
Huang Y; Dai H; Guo QN
Apoptosis; 2012 Aug; 17(8):749-61. PubMed ID: 22610481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
